RadNet, Inc. will discuss its second quarter 2026 financial results during a conference call scheduled for Monday, August 10, 2026. The national provider of diagnostic imaging services will host the briefing at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time) to review its performance for the period.

Investors can access the live call by dialing 844-744-1280 in the United States or 412-564-6465 for international callers. A simultaneous and archived webcast will be available online, allowing stakeholders to listen to the management's discussion on the quarterly outcomes.

Access Details

For those unable to attend the live session, RadNet will provide an archived replay of the conference call. The replay can be accessed by dialing 844-512-2921 from the U.S. or 412-317-6671 from international locations. Participants must use passcode 10210872 to listen to the recording.

Corporate Profile

RadNet, Inc. operates a network of owned and operated outpatient imaging centers across multiple states, including Arizona, California, Florida, and New York. The company provides radiology information technology and artificial intelligence solutions under the DeepHealth brand. With over 11,000 employees, RadNet serves the diagnostic imaging industry through teleradiology professional services and related products.

DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., has received FDA 510(k) clearances for two new functionalities within its Breast Suite, aimed at enhancing cardiovascular risk evaluation and cancer detection during mammography screenings. The newly cleared tools, Breast Arterial Calcification (BAC) Assessment and Mammo Dx, are now commercially available in the United States. These additions reinforce the Breast Suite as a modular, interoperable portfolio of applications addressing clinical needs across breast cancer screening and diagnostic pathways.

BAC Assessment and Mammo Dx

The BAC Assessment tool is applied to standard screening mammograms to automatically identify breast arterial calcifications, which are potential early indicators of cardiovascular disease. It analyzes both standard 2D (FFDM) and 3D (DBT) mammograms, flagging calcifications within the radiology workflow without requiring additional imaging. In clinical performance testing, the BAC Assessment demonstrated more than 90% sensitivity and more than 88% specificity in identifying arterial calcifications across dense and non-dense breast tissue.

Mammo Dx, formerly known as ProFound Pro with prior exam integration, enables the automatic processing of prior and current studies. This functionality tracks prior lesions and distinguishes new ones, with the goal of improving cancer detection rates and reducing recalls. By comparing breast tissue over time, Mammo Dx helps radiologists identify subtle changes that may be undetected in a single-exam read.

Clinical Impact and Deployment

Niccolo Stefani, MD, Business and Product Leader, Population Health & Clinical AI at DeepHealth, highlighted the strategic value of these tools. "BAC Assessment and Mammo Dx are proof points of that strategy: one adds a cardiovascular evaluation to a routine breast cancer screening mammogram and the other incorporates changes from past mammogram exams into current mammograms to improve cancer detection," Stefani said.

The BAC Assessment will be deployed across RadNet imaging centers in the U.S., providing additional real-world validation of its capability. Mammo Dx supports more informed clinical decision-making by bringing prior findings into the interpretation process, aiming to reduce false positives and better determine when additional diagnostic procedures are warranted.

Breast Suite Portfolio

With these clearances, DeepHealth's Breast Suite now includes BAC Assessment, Mammo Dx, automated breast density assessment, and future cancer risk assessment. The suite also features workflow tools designed to elevate radiologist performance and enhance operational efficiency. Currently, components of the Breast Suite support diagnostic accuracy and standardization of care across more than 10 million mammograms performed annually worldwide.